Bromocriptine, a dopamine agonist, has potential implications for enhancing working memory and cognitive function, yet pharmaceutical companies have largely overlooked this avenue despite existing data. The tight link between dopamine depletion and impaired cognitive processes raises questions about the industry's reluctance to develop cognitive-enhancing drugs. Insights reveal a missed opportunity for significant therapeutic advancements in executive function.